Insider Profile · SEC Form 4 Activity · Trailing 90 Days
Kiselak Tomas
Over the trailing 90 days, Kiselak Tomas (Director at Oruka Therapeutics, Inc.) traded $719.7M of stock (net selling $679.7M) across 6 companies, per 14 SEC Form 4 transactions.
- Role
- Director
- Window
- Trailing 90 days · 14 transactions · CIK 1830177
- Net activity
- −$679.7M ($20.0M bought · $699.7M sold)
By Company (Trailing 90 Days)
Transactions (14)
| Date | Symbol | Type | Shares | Value | Description |
|---|---|---|---|---|---|
| 2026-07-16 | CBIO | Buy | 525.9K | $7.6M | Open market or private purchase |
| 2026-07-16 | CBIO | Buy | 853.5K | $12.4M | Open market or private purchase |
| 2026-07-01 | VRDN | Buy | 32.3K | $0 | Grant, award or other acquisition |
| 2026-07-01 | ORKA | Sell | 42.6K | $0 | Conversion of derivative security |
| 2026-07-01 | ORKA | Sell | 3.6M | $300.0M | Open market or private sale |
| 2026-07-01 | ORKA | Buy | 3.6M | $0 | Conversion of derivative security |
| 2026-06-23 | SYRE | Buy | 666.7K | $0 | Conversion of derivative security |
| 2026-06-23 | SYRE | Sell | 4.7M | $399.7M | Open market or private sale |
| 2026-06-23 | SYRE | Sell | 16.7K | $0 | Conversion of derivative security |
| 2026-06-09 | APGE | Buy | 7.7K | $0 | Grant, award or other acquisition |
| 2026-06-09 | JBIO | Buy | 34.8K | $0 | Grant, award or other acquisition |
| 2026-06-02 | CBIO | Buy | 11.1K | $0 | Grant, award or other acquisition |
| 2026-06-02 | ORKA | Buy | 9.1K | $0 | Grant, award or other acquisition |
| 2026-05-27 | SYRE | Buy | 8.0K | $0 | Grant, award or other acquisition |
Activity shown covers the trailing 90 days of SEC Form 4 filings. "Buy" and "sell" follow the SEC acquired/disposed codes and include compensation events (grants, option exercises, tax withholding) unless noted. Historical fact, not investment advice.
Follow Kiselak's next move
Real-time Form 4 alerts, insider track records, and cluster detection — matched to your watchlist.